← All trials
NCT04406649
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Satsuma Pharmaceuticals, Inc.Lead sponsor
- Satsuma Pharmaceuticals, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.